Evogene swings to Q3 net loss of $2.86 million
EVGN•
EVGN•Evogene reported a third-quarter 2026 net loss of $2.86 million, compared with net income of $5.2 million a year earlier, as revenue fell 55% to $141,000. Cash, cash equivalents and short-term bank deposits totaled approximately $9.2 million at September 30.
Evogene swung to a third-quarter 2026 net loss of $2.86 million from net income of $5.2 million a year earlier. Revenue fell 55% year over year to $141,000, mainly due to the Bayer license and collaboration agreement ending in May 2026. Cash, cash equivalents and short-term bank deposits totaled approximately $9.2 million at September 30, and third-quarter cash usage was approximately $2.4 million.
Evogene said its internal acute graft-versus-host disease drug discovery program advanced toward IND-enabling studies, with candidates showing nanomolar potency. Its subsidiary AgPlenus identified fungicide compounds that reduced Septoria disease severity by up to 75% versus untreated controls in plant tissue assays.